The t(15;17)(q22;q12) translocation is the cytogenetic hallmark of acute promyelocytic leukemia (APL). The PML and retinoic acid receptor-& (RA&) transcription factor genes are involved at the translocation breakpoint. To elucidate the biologic function of PML, antipeptide antibody against PML protein was raised in rabbits. This antibody was able to detect a 90-kD PML protein and a 110-kD PML-RARa fusion protein by Western blotting and a nuclear speckled pattern in all cell lines by immunofluorescent staining. In K562 and NIH/3T3 cells transfected with a PML expression plasmid, we found PML to be associated with the nuclear matrix. Our results also showed that PML is a phosphoprotein. A weak signal was detected in a Western blot containing the immunoprecipitated PML protein using the phosphotyrosine-specific monoclonal antibody. Therefore, at least one of the sites B ECAUSE THE NONRANDOM chromosome translocation t(15; 17)(q22;q12) can be found in over 95% of patients with acute promyelocytic leukemia (APL),'.' one can infer that genes involved in this unique translocation event play a role in its pathogenesis. Studies from several laboratories have confirmed that the t( 15; 17) translocation occurs within the zinc finger transcription factor gene, PML, and the retinoic acid receptor-a (RARa) gene."' Because an extremely high number of APL patients can be induced to complete clinical remission by all-trans retinoic acid (ATRA),'"' it is believed that disruption of the RARa gene by the translocation plays a role in the leukemogenesis. However, evidence indicates that, when the myeloid leukemia cell line HL-60 loses its RA inducibility, this inducibility can be completely restored by other forms of RAR or retinoic X receptor (RXR)," suggesting that the loss of RARa function by APL cells may not be a critical event in leukemogenesis. Recent reports showed that the fusion protein PMLRARa encoded from the t(15; 17) breakpoint is responsible for RA inducibility in APL, because transfection of the PMLRARa cDNA into the human myeloid leukemia cell line U937 conferred RA inducibility." Furthermore, APL-derived NB4 cells that lose their RA inducibility also lose expression of the PML- was phosphorylated by a tyrosine kinase. From our analysis of the phosphoamino acids of the PML protein by complete hydrolysis and thin-layer chromatography, we concluded that both tyrosine and serine residues of PML are phosphorylated. To investigate whether expression of the PML protein is cell-cycle related, HeLa cells synchronized at various phases of the cell cycle were analyzed by immunofluorescence staining and confocal microscopy for PML expression.
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We found that PML was expressed at a lower level in S, G2, and M phases and at a significantly higher level in G1 phase.
Our study showed that PML has many similar properties compared with the tumor suppressor, eg, Fib. These findings further support the important role of PML in APL pathogenesis.
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A recent report by Kastner et al" showed that the PMLRARa fusion protein can form a stable heterodimer with PML but not with RARa and that PML-RARa appears t o be a much more stable protein. This finding indicates that heterodimer formation between the fusion protein and PML should occur in the APL cells. It was also found that heterodimer formation between PML and PML-RARa results in a cytoplasmic retention, contrary to the nuclear localization of PML. Because one of the PML genes is disrupted by the t( 15; 17) translocation, a combination of these two events could result in sequestration of the normal PML function. These results suggest that PML-RARa can act as a dominant negative inhibitor of PML in the APL cells. Therefore, disruption of the PML function in APL may represent an event in the development of APL.
The t(l5; 17) translocation breakpoint transcribes both fusion transcripts PML-RARa and RARa-PML.5.6,14-" The cDNA of both fusion transcripts have been cloned and characterized. The PML-RARa protein consists of all the important functional domains of RARa and PML and has been shown to be an RA-dependent transcription factor whose cell-type and target specificity differ from that of normal PML-RARa cDNA into the human myeloid leukemia cell line U937 result in an inhibition of growth factor (eg, vitamin D3 and transforming growth factor-01) inducibility. That group also showed that the stable transfectants expressing the PML-RARa fusion protein suppress programmed cell death. Thus, inhibition of growth factor inducibility and apoptosis can apparently result in differentiation arrest and continuous proliferation. Therefore, expression of PMLRARa alone is sufficient to recapitulate the phenotype of APL.
Perez et a]*' reported that PML-RARa can effectively form a heterodimer with RXR, resulting, in turn, in cytoplasmic retention of the fusion protein through the RARa portion. Therefore, PML-RARa can also act as a dominant negative inhibitor against RXR function in APL cells. RXR is an important component of the RA-responsive pathway, and heterodimer formation between RXR and thyroid hormone receptor, RAR, or vitamin D3 receptor (VDR) results RARa.'.6.hh Grignani et The etiologic significance of PML in APL cells remains relatively unknown. However, it is obvious that sequestration of the PML function in APL cells plays an important role in APL pathogenesis. Here, we report on our study of the cellular function of PML in which we used an affinity-purified antipeptide antibody to PML. Immunofluorescent staining of the PML protein showed a unique nuclear speckled pattern in all cell types tested except the APL cells, which showed a nuclear microspeckled pattern. We showed that PML is associated with the nuclear matrix and that PML is a phosphoprotein. Analysis of the phosphoamino acids of PML indicated that both the serine and tyrosine residues are phosphorylated. Our result also showed that PML expression is cell-cycle related.
MATERIALS AND METHODS
Preparation of antipeptide antibody against PML. The antipeptide antibody against PML used in this study was raised in rabbits by means of a synthetic peptide comprising amino acids 352 to 36615 of the PML protein's predicted amino acid sequence. The synthetic peptide was coupled to keyhole limpet hemocyanin according to the method of ReichlinZ5 and inoculated subcutaneously into multiple sites on the back of a rabbit. High-titer antibody was collected and used directly for Western blotting. The antipeptide antibody was affinity-purified on a peptide-linked Affi-gel 10 column prepared according to the manufacturer's instructions (Bio-Rad Laboratories, Richmond, CA). In brief, 1 g of Affi-gel 10 was washed with 5 to 10 mL of distilled H20 and mixed with 5 mg of synthetic peptide in 5 mL of coupling buffer (0.1 mol/L MOPS, pH 7.3, and the coupling reaction was performed overnight at 4°C. The coupling gel was blocked by incubating it in blocking buffer (1 m o m ethanolamine, pH 8.0) for 1 hour at room temperature. The peptide-coupled Affi-gel was transferred and packed into a small column (eg, a 2-mL disposable pipet) and then was washed with distilled H20 until it was free of peptide as monitored by reading the ODzm. The column was then equilibrated with 20 mL of equilibration buffer (IO mmoV L Tris-HCI [pH 7.41, 0.15 mol/L NaC1). Next, 3 mL of the hightiter antisera was loaded onto the column and washed with 20 mL of equilibration buffer. The column was then washed with 2 mL of 2 m o m NaCl followed by 20 mL of equilibration buffer. The specifically bound antipeptide antibody was eluted with 10 mL of elution buffer (0.1 molL citric acid, pH 2.5) and neutralized to pH 7.0 immediately with 2 mom Tris-HCI. The affinity-purified antipeptide antibody was concentrated and stored in the presence of 1% bovine serum albumin (BSA) and 0.01% thimerosal.
Cell culture. NIH13T3, HeLa, and SK-OV-3 cells were cultured in Dulbecco's modified Eagle's medium containing 10% bovine calf serum (GIBCOIBRL, Gaithersburg, MD) in a humidified COz incubator at 37°C. K562, NB4, Kasumi-l, HL-60, Raji, and Daudi cells were cultured in RPM1 1640 medium supplemented with 10% fetal bovine serum. The NB4 cells were induced to differentiate in the presence of m o m ATRA (Sigma Chemical CO, St Louis, MO) as previously described." Cell maturation was determined by a standard nitroblue tetrazolium reduction assay in the presence of phorbol myristate acetate."
Gene transfecrion. The NIW3T3 cells (5 x 10') were transfected either with pSG5PML expression plasmids,28 which carry the fulllength PML cDNA driven by the simian virus 40 early promoter, or with expression plasmids of PML-RARa (MylRAR-A; obtained from Dr P. Chambon, Strasbourg, France)I4 by lipofectamine-mediated gene transfer according to the manufacturer's procedure (GIBCOIBRL). The transfected cells were cultured for 24 hours, after which the protein fraction was isolated and analyzed by Westem blotting.
Western immunoblor analysis. Samples of the transiently transfected cells were prepared by lysing the cells in RIPA buffer containing 0.12 mol/L NaCI, 0.01 m o m Tris-HC1 (pH 7.61, 1 mmoll L EDTA, 1 % NP-40, 1 % deoxycholate, 0.1 % sodium dodecyl sulfate (SDS), and proteinase inhibitors (10 pglmL of aprotinin, 10 pglmL of leupeptin, 1 mmoliL phenylmethylsulfomyl fluoride, 2 pg1mL pepstatin, and 50 mmoliL sodium fluoride). The cell lysate was incubated on ice for 15 minutes and centrifuged at 5,OOOg for 15 minutes at 4°C. The protein fractions were mixed at a ratio of 1:l with 2X SDS sample buffer (0.1 m o m Tris-HCI [pH 6.81, 0.2 mol/L dithiothreitol, 4% SDS, 0.2% bromophenol blue, and 20% glycerol) and boiled for 5 minutes before being subjected to 7.5% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were then transferred onto nitrocellulose filters (Schleicher & Schuell, Inc, Keene, NH) in a buffer containing 25 mmom Tris, 192 mmol/L glycine, and 20% methanol. Filters were then blocked by incubating them overnight in Tris-buffered saline (10 mmol/L Tris [pH 8.01, 150 mmol/L NaCl) containing 5% nonfat dried milk. The filters were then incubated for 2 hours with PML antibody. Antibody reactions were detected by incubating the filters with alkaline phosphatase-conjugated antirabbit IgG (Bio-Rad Laboratories), washing them, and then developing them in a buffer containing 100 mmol/L Tris-HCI (pH 9.5). 100 mmol/L NaC1, 5 mmol/L MgCIZ, 330 pg/mL of nitroblue tetrazolium, and 150 pg/mL of 5-bromo-4-chloro-3-indolyl phosphate for 10 to 20 minutes.
Immunofluorescence microscopy. Immunofluorescence staining of the PML protein was performed by using the affinity-purified antipeptide antibody described above. Cells were fixed in 4% formaldehyde for 20 minutes and in 0.1 % Triton X-100 for 10 minutes, followed by 3 washes in phosphate-buffered saline (PBS) containing 0.1% BSA. Cells were then incubated in the washing buffer for 20 minutes at room temperature and were incubated with the affinitypurified PML antipeptide antibody. After 30 minutes at 37"C, cells were then incubated with goat antirabbit IgG-fluorescein isothiocyanate secondary antibody (Boehringer Mannheim Corp, Indianapolis, IN) for 30 minutes, washed with 0.1% BSA in PBS, and mounted with Vectashield mounting medium (Vector Laboratories, Inc, Burlingame, CA). The fluorescently stained cells were analyzed through a Nikon (New York, NY) fluorescence microscope. Confocal microscopy analysis was performed by using a Zeiss (New York, NY) laser scanning confocal microscope (LSM). Flurochromes were stimulated with a 10-mW argon laser providing monochromatic 488-nm light. Signals were collected through a 540120 band pass filter. Image collection was obtained with the aid of LSM version 2.0 confocal microscopy software supplied by Zeiss. Digital images were stored on a Macintosh Quadra 900 computer after being transferred from the Zeiss computer using a GPIB interface. The interface software was written by Biological Detection Systems (Pittsburgh, PA), To determine the specificity of the antibody, the antipeptide antibody was blocked by incubation with 50 pg/mL of the synthetic peptide at 37°C overnight before being used in the immunofluorescence staining experiment. After immunofluorescence staining, chromosomal DNA from the fixed cells was stained with Hoechst 33258 at a concentration of 0.4 pg/mL for 5 minutes, washed, and examined under a fluorescence microscope. After incubation at 33°C for 60 minutes, cells were centrifuged for 2 minutes at 12.0(H)g. The resulting supernatant was designated fraction no. 2, and the resulting pellet was resuspended in S v01 of 0.25 mol/L ammonium sulfate, left on ice for S minutes. and centrifuged as before. The resulting supernatant was designated as fraction no. 3. and the resulting pellet was resuspended in S v01 of 2 mol/L NaCI. incubated on ice for S minutes and centrifuged as before. The resulting supernatant and pellet were designated as fractions no. 4 and S. respectively. Each supernatant fraction was concentrated to a final volume of S0 pL before being subjected to Western blot analysis.
Cell-cycle s~,?rltroni~ation. HeLa cells were synchronized at the G,/S boundary by double thymidine blocking as previously described.'" Briefly. cells at a concentration of 3.5 X IO%nL were cultured in the presence of 2 mmol/L thymidine in medium (10% bovine fetal serum in Dulbecco's modified Eagle's medium) for 12 to 16 hours. Cells were washed and cultured in regular medium for 8 to 10 hours and then again cultured for 12 to 16 hours in the presence of 2 mmol/L thymidine. Cells were released from the G , / S block by washing 3 times with PBS and cultured in regular medium. Cells were harvested after 2 and 4 hours (S phase), 8 hours (G2 phase), 10.5 hours (M phase), and 12 hours and 14 hours (G, phase), as described.'" Synchronization of cells at the S phase was confirmed by 'H-thymidine incorporation into the cells as previously described." Cells synchronized at the M phase were confirmed by staining with Hoechst 33258 and were examined under a fluorescent microscope.
Annl~sis of phosphoplation of the PML protein. Phosphorylation of the PML protein was analyzed by incorporation of "P-orthophosphate and immunoprecipitation of the radiolabeled PML protein using the NIH13T3 cells transfected with pSGSPML. The "P-labeled PML protein was immunoprecipitated with the affinity-purified PML antipeptide antibody, subjected to SDS-PAGE, and autoradiographed as described previously.'' Phosphorylation of the PML protein was also determined by dephosphorylation with alkaline phosphatase and by Western blot analysis. Briefly, total cellular protein (300 wg) isolated from the NIH/3T3 cells transfected with pSGSPML was resuspended in 0.5 mL of NET-N buffer (20 mmol/L Tris [pH 8.01, 100 mmol/L NaCI, I mmol/L EDTA. 0.5% NP-40, S0 mmol/L NaF, 0.2 mmol/L Na3V04, 1 mmol/L phenylmethylsulfonyl fluoride, 10 mglmL leupeptin. and 10 p g h L aprotinin) and incubated with IO pL PML antibody for I hour at 4°C. Protein A-agarose (Oncogene Science. Manhasset, NY) was then added and incubated at 4°C overnight. Immunoprecipitated PML protein was collected by centrifugation, and the pellet was washed 4 times with NET-N buffer. The pellet was resuspended in 40 pL of buffer containing 1 0 0 mmol/L Tris (pH 8.0). S mmol/L MgC12, I W mmol/L NaCI, and proteinase inhibitors, followed by the addition of 10 U of calf-intestine alkaline phosphatase (Boehringer Mannheim Corp). The reaction mixture was incubated at 37°C for 30 minutes, and then washed 2 times in NET-N buffer. Finally, the pellet was resuspended in gel-loading buffer and boiled for S minutes before being subjected to 10% SDS-PAGE. Western blot analysis of the PML protein with the phosphotyrosine-specific monoclonal antibody RC 20 (Transduction Laboratories, Lexington, KY) was performed as described in the previous section.
A~ralysis of phosphoamino aci& Analysis of phosphoamino acids in the PML protein was performed as described by Liu et al." Briefly, NIH13T3 ( I X 10") cells were transiently transfected with pSGSPML by lipofectamine mediated gene transfer according to the manufacturer's instructions (GIBCOIBRL). The transfected cells were metabolically labeled with "P-orthophosphate (0.5 mCilmL; ICN, Irvine, CA) as described.'" The "P-labeled protein was immunoprecipitated with the PML antipeptide antibody and electrophoresed on a 10% SDS-PAGE. The band containing the radiolabeled PML protein was excised from the dried gel using the autoradiogram as a template. The protein was extracted from gel slice in 2 mL of S0 mmol/L ammonium bicarbonate (pH 8 5 ) . 0 . 1 % SDS. and 720 mmol/L 2-mercaptoethanol by boiling for S minutes and then agitating at 37°C overnight. Protein was precipitated with 20% ice-cold trichloracetic acid and hydrolyzed with 6 N hydrochloric acid for 1.5 to 2 hours at 1 10°C. The clarified supernatant was fractionated on thin-layer chromatography in the presence of phosphoserine, phosphothreonine, and phosphotyrosine. Radioactive phosphoamino acids were detected by autoradiography, and then the plate was subsequently treated with ninhydrin to show the position of the authentic phosphoamino acids.
RESULTS
Characterization and aflnifyw"cation of the PML antipeptide antibody. To study the expression of PML protein in leukemia cells, antipeptide antibody was raised in rabbits against a synthetic peptide of amino acids 352 to 366 of the PML protein.Is High-titer antisera was collected and affinitypurified on a peptide-coupled Affi-gel I O column prepared as described in Materials and Methods. The specific activity of the affinity-purified antipeptide antibody was substantially improved. To examine the specificity of this purified antipeptide antibody, Western blot analysis of the PML and PMLRARa proteins was performed. As shown in Fig IA, this antibody detected a 90-kD PML protein in the NIH/3T3 cells transfected with pSGSPML, which carries the full-length cDNA of PML driven by simian virus 40 early promoter. We performed in vitro transcription and translation of the pSG5PML plasmid, and a 90-kD PML protein band was observed (data not shown). PML migrates as a 90-kD protein instead of as a predicted 70-kD protein, a trait also noted by P. Kastner and P. Chambon (personal communication, Fig 1 A. the antipeptide antibody also detected a I IO-kD protein band in the NIH/3T3 cells transfected with the expression plasmid of PML-RARa. Our antibody also detected a 1 IO-kD PML-RARa fusion protein in the NB4 cells (Fig IB) . Therefore, these results confirm that our antibody recognizes the PML protein.
September 1994). As shown in
PML proteirl e.q>re.ssiort in 1~7riorr.s cell 1irw.s. To examine PML protein expression in various cell types. we performed immunofluorescence staining involving the affinitypurified PML antipeptide antibody. As shown in Fig 2, a nuclear speckled pattern similar to the PML staining pattern previously was detected in all cell types. This nuclear speckled signal was blocked when the antibody was preincubated with the specific peptide (unpublished data). This result showed that our antibody can specifically detect the PML protein in vivo. Immunofluorescence staining using our affinity-purified PML antipeptide antibody detected a nuclear speckled pattern of PML in all cell types. Two different types of nuclear speckled patterns (bright or weak). similar to the PML oncogenic domains. were found in all cell types. Some of the signals were also found in the cytoplasm.
A.s.socirrtiorl of PML protein w i t h the rlrrclecrr mcrtri.~. The nuclear matrix. an insoluble nuclear skeletal framework of the nucleus, is defined as a dynamic structural subcomponent of the nucleus that directs functional domains of the chromatin to provide sites for specific control of nucleic a c i d~.~" .~' Actively transcribed genes. the site of RNA processing including the small nuclear ribonucleoprotein particles (snRNPs). hormone receptors. and transcription factors have a l l been shown to be associated with the nuclear matrix. Recent studies in our laboratory to investigate PML's ability to transactivate several promoter-CAT constructs in a series of cotransfection experiments showed that PML is a promoter-specific transcription suppressor.'x Thus. we investigated whether PML is associated with the nuclear matrix.
In our study. K562 and NIH/3T3 cells transfected with pSGSPML were subjected to the nuclear matrix fractionation procedure described in Materials and Methods. The results of Western blot analysis of the protein samples isolated from different fractions are shown in Fig 3. This result showed that a substantial quantity of the 90-kD PML protein was detected in fraction no. S of the nuclear matrix fraction isolated from the K562 cells and in NIH/3T3 cells transfected with pSGSPML. A very weak protein band of 90-kD was also detected in fraction no. S of the NB4 cells (unpublished data).
PML as (I p h o .~~~h o~~r o t~i r l in vivo. According to the predicted amino acid sequence of PML, several potential sites of phosphorylation have been found. This indicates that the PML protein may be phosphorylated in vivo. We used several different approaches to investigate this possibility. Our results presented in Fig 4 showed that PML is indeed phosphorylated in vivo. In these studies the PML protein was immunoprecipitated with affinity-purified PML-specific antipeptide antibody, treated with alkaline phosphatase. and subjected to Western blot analysis. As shown in Fig 4. lanes I and 2. the upper band of the PML protein was lost after alkaline phosphatase treatment. This suggests that the slowmoving band represents the phosphorylated form. That PML is a phosphoprotein was further shown by the ."P-orthophosphate incorporation experiment. The result shown in Fig 4.  lanes 3 and 4, showed that the immunoprecipitated PML protein and was phosphorylated and radioactively labeled. For
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Therefore, our results convincingly showed that PML is phosphorylated in vivo. Our results also showed that the phosphotyrosine-specific monoclonal antibody RC 20 can immunoreact with the 90-kD PML protein (Fig 4, lane S ) . Thus. our study showed that PML is a phosphoprotein and that at least one of its sites is phosphorylated by a tyrosine kinase.
To confirm the above findings, the NIH/3T3 cells were transfected with pSGSPML. and the metabolically labeled PML protein was immunoprecipitated with PML antipeptide antibody. The phosphoamino acids were determined by complete hydrolysis and thin-layer chromatography. Figure S showed that both tyrosine and serine residues of the PML protein are phosphorylated. The degree of phosphorylation appears to be much stronger in the serine residue (Fig S,  lane 2) . Under the conditions of acid hydrolysis as described in Materials and Methods, tyrosine residue is unstable after two hours of treatment. The result of Fig S, lane I , shows that the phosphotyrosine residue was completely degraded after this treatment. Therefore, these studies confirm that PML is a phosphoprotein and is phosphorylated by a tyrosinekerine kinase(s).
E.vpression of PML clltrirtSq various cell-cycle phases. As our studies show, PML appears to have many properties similar to the tumor suppressor, eg, Rb. This includes its growth-suppressor function. its association with the nuclear matrix. and phosphorylation of both its forms in vivo. Because PML was expressed in all the human cell lines tested in our laboratory, we investigated whether its expression is cell-cycle related. We chose to use the HeLa cells for this study. Expression of the PML protein during various phases of cell cycle was analyzed by immunofluorescent staining and confocal microscopic analysis. As shown in Fig 6, immunofluorescence staining showed that PML expression was much lower in cells synchronized in the S , G?, and M phases. Its expression was significantly higher in cells synchronized in the G , phase. Thus. from these studies, we conclude that expression of PML is cell-cycle related, with its highest expression in the G, phase.
DISCUSSION
The t(1S; 17) translocation is the cytogenetic hallmark of APL. Both transcription factor genes RARa and PML are disrupted, and the potentially oncogenic fusion protein PMLRARa is created by the translocation. As confirmed by several laboratories, APL patients can be induced to complete clinical remission by treatment with ATRA. Therefore, APL provides an excellent model system for studying the molecular mechanism of leukemogenesis.3x2" The predicted amino acid sequence of PML consists of a proline-rich domain that resembles the transcription-activating domain of some genes."f' Three clusters of zinc finger motif were found further downstream, followed by an a-helical region responsible for homodimer and heterodimer formation between PML and PML-RARa." A potential phosphorylation site with a serine-proline rich domain was found near the carboxy terminal of the PML protein.
Immunofluorescence staining of the PML protein in APL cells showed a nuclear microspeckled pattern different from the normal nuclear speckled patterns or PML oncogenic domains. After induced differentiation by ATRA, a normal nuclear speckled pattern of PML was observed.".25 Together, these findings indicate that, after ATRA treatment, differentiation of the NB4 cells is associated with a redistribution of the PML protein to its normal location. Because increased For personal use only. on October 30, 2017. by guest www.bloodjournal.org From expression of PML by transfection of its cDNA into the NB4 cells can suppress clonogenicity in a soft agar assay,'x it is possible that PML redistribution as a result of differentiation induction could be the result of an increased cellular level of functional PML because of release from the PMUPMLRARa heterodimer or by increased PML gene expression induced by ATRA treatment. Northern blot analysis indicated that the steady-state PML mRNA level was unaffected by ATRA treatment (K.-S. Chang, unpublished result); thus, it is possible that an altered pattern of PML in NB4 cells after ATRA-induced differentiation is a result of a redistribution of the PML protein. It is currently unknown whether PML rearrangement is directly related to NB4 differentiation.
Recent cotransfection studies in our laboratory showed that PML but not PML-RARa is a promoter-specific transcription suppressor.'x Our studies also showed that PML is a growth suppressor. as evidenced by the following findings: The finding that PML is a tyrosinekerine phosphoprotein sheds important light on its role in cellular function. The biologic functions of many important cellular regulatory proteins. eg, Rb and Neu, are regulated by phosphorylation/ dephosphorylation.4"-JZ PML is a growth suppressor and is also a promoter-specific transcription suppressor." Its involvement in the t( IS; 17) translocation and its inactivation in APL cells suggests that PML may be a novel tumor suppressor. Therefore, because all cell lines analyzed in our laboratory and most cells in normal human bone marrow express the PML protein, as determined by immunofluorescence staining, it is possible that the biologic function of PML may be regulated by a phosphorylation/dephosphorylation mechanism similar to that for Rb. As shown in Fig 6. we found that expression of the PML protein is cell-cycle related, with its highest level occurring in the G , phase. It will be interesting to determine whether phosphorylation/ dephosphorylation of the PML protein is regulated during different phases of the cell cycle. This information will be important in understanding the biologic function of PML.
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The finding that PML is associated with the nuclear matrix is not unexpected, because other nuclear matrix proteins, eg, snRNP, also show, on immunofluorescence staining,3b a nuclear speckled pattern similar to that for PML. Our results suggest that both the phosphorylated and unphosphorylated forms of the PML proteins are associated with the nuclear matrix, because all the PML proteins (both the upper and lower bands) were recovered from fraction no. S of the nuclear matrix preparations (Fig 3) . This is different from the case for Rb, in which only the hypophosphorylated form is associated with the nuclear matrix during the G , phase of the cell cycle." As shown in Fig 2, two different types of nuclear speckled patterns (bright and weak) were found in all cell types, and both signals may be associated with the nuclear matrix. However, it is currently unknown whether the PML protein is phosphorylated in both locations. We speculate that PML may exert its biologic function by interacting with other protein factors within the nuclear matrix. In addition, phosphorylation/dephosphorylation of the PML protein does not seem to have any effect on its nuclear matrix association but may affect interaction with other protein factors. Further study will be necessary to elucidate these possibilities. 
